PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET
Ultragenyx reported Q3 2026 revenue of $173M (up 8% YoY from $160M) and a net loss of $118M ($1.16 per share), narrower than the $180M loss a year ago. The company announced a 20% headcount reduction, termination of two pipeline programs (GTX-102, UX701), and expects full-year GAAP profitability in 2027. Two FDA approvals (GENGLYCOS, FAYUVI) were received, and two Priority Review Vouchers were sold for a combined $413M. The EPS of -$1.16 missed the consensus estimate of -$0.75, a miss of 54.7%.